On September 19, 2022 Angiex, developer of Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) therapies for solid cancers, reported the submission of an Investigational New Drug (IND) application on its lead product, AGX101, to the FDA (Press release, Angiex, SEP 19, 2022, View Source [SID1234621830]). Pending feedback from the agency, Angiex looks to begin enrolling the first patients in the clinical trial in Q4 of this year. The Phase 1 trial will focus on solid cancer patients with late stage disease who have few or no therapeutic options.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AGX101 is a humanized TM4SF1-directed antibody and microtubule inhibitor antibody drug conjugate (ADC) being developed as an intravenously (IV) administered therapeutic. The TM4SF1-directed antibody is linked to a tubulin-inhibiting maytansine payload via a noncleavable covalent linker and site-specific conjugation to an engineered cysteine.

TM4SF1 is a novel ADC antigen that is highly expressed in tumor cells and tumor associated vascular endothelium, and is differentiated by its internalization to the nucleus. AGX101 has been shown to be highly potent both in vitro and in vivo, and has achieved complete tumor regressions in multiple human tumor xenograft models in mice. AGX101 is the first in Angiex’s pipeline of Nuclear Delivery Antibody-Drug ConjugatesTM, and proof of concept for Angiex’s Nuclear Delivery PlatformTM.